NANOPARTICULATE SYSTEMS FOR DRUG DELIVERY AND TARGETING TO THE CENTRAL NERVOUS SYSTEM

Risultato della ricerca: Article

48 Citazioni (Scopus)

Abstract

Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood–brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotein inhibition. This review summarizes the main brain targeted nanoparticulate carriers such as liposomes, lipid nanoparticles, polymeric nanoparticles, and micelles with great potential in drug delivery into the CNS.
Lingua originaleEnglish
pagine (da-a)670-677
Numero di pagine8
RivistaCNS NEUROSCIENCE & THERAPEUTICS
Volume17
Stato di pubblicazionePublished - 2011

Fingerprint

Drug Delivery Systems
Central Nervous System
Nanoparticles
Brain
Central Nervous System Agents
Brain Diseases
Micelles
P-Glycoprotein
Neurosciences
Endocytosis
Liposomes
Pharmaceutical Preparations
Industry
Lipids
Injections
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health
  • Physiology (medical)
  • Pharmacology (medical)

Cita questo

@article{97bdc36e793a4a0fb1045ccd29873412,
title = "NANOPARTICULATE SYSTEMS FOR DRUG DELIVERY AND TARGETING TO THE CENTRAL NERVOUS SYSTEM",
abstract = "Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood–brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotein inhibition. This review summarizes the main brain targeted nanoparticulate carriers such as liposomes, lipid nanoparticles, polymeric nanoparticles, and micelles with great potential in drug delivery into the CNS.",
keywords = "Alzheimer’s disease, Movement disorders/Parkinson’s disease, Multiple sclerosis, Neuropsychopharmacology.",
author = "Giovanna Pitarresi and Gennara Cavallaro and Craparo, {Emanuela Fabiola} and Bond{\`i}, {Maria Luisa}",
year = "2011",
language = "English",
volume = "17",
pages = "670--677",
journal = "CNS NEUROSCIENCE & THERAPEUTICS",
issn = "1755-5930",

}

TY - JOUR

T1 - NANOPARTICULATE SYSTEMS FOR DRUG DELIVERY AND TARGETING TO THE CENTRAL NERVOUS SYSTEM

AU - Pitarresi, Giovanna

AU - Cavallaro, Gennara

AU - Craparo, Emanuela Fabiola

AU - Bondì, Maria Luisa

PY - 2011

Y1 - 2011

N2 - Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood–brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotein inhibition. This review summarizes the main brain targeted nanoparticulate carriers such as liposomes, lipid nanoparticles, polymeric nanoparticles, and micelles with great potential in drug delivery into the CNS.

AB - Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood–brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotein inhibition. This review summarizes the main brain targeted nanoparticulate carriers such as liposomes, lipid nanoparticles, polymeric nanoparticles, and micelles with great potential in drug delivery into the CNS.

KW - Alzheimer’s disease

KW - Movement disorders/Parkinson’s disease

KW - Multiple sclerosis

KW - Neuropsychopharmacology.

UR - http://hdl.handle.net/10447/61235

M3 - Article

VL - 17

SP - 670

EP - 677

JO - CNS NEUROSCIENCE & THERAPEUTICS

JF - CNS NEUROSCIENCE & THERAPEUTICS

SN - 1755-5930

ER -